FDA Approves Expanded Indication for Pembrolizumab for cSCC

On July 6, 2021, the U.S. Food and Drug Administration (FDA) approved an expanded label for pembrolizumab as a monotherapy treatment for patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Read Merck's announcement.

Posted 7/6/2021